TTK Healthcare (TTKHLTCARE) Fundamentals 2026 — P/E 21.6x, Revenue Analysis | SniperIQ
TTK Healthcare (TTKHLTCARE) is a India-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₹1,422 Crore, trading at ₹1006.00 on the NSE. This SniperIQ fundamentals page covers TTK Healthcare's valuation (P/E 21.6x, P/B 1.3x), profitability (net margin 7.7%), revenue (₹857 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is TTK Healthcare's market cap?
TTK Healthcare (TTKHLTCARE) has a market capitalization of approximately ₹1,422 Crore, trading at ₹1006.00 on the NSE. Market cap moves with the live share price.
What is TTK Healthcare's P/E ratio?
TTK Healthcare's trailing twelve-month P/E ratio is 21.6x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is TTK Healthcare?
TTK Healthcare runs a net profit margin of 7.7%, a gross margin of 42.8%, and an operating margin of 2.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does TTK Healthcare generate?
TTK Healthcare reported revenue of ₹857 Crore for fiscal year 2026, with net income of ₹66 Crore and earnings per share (EPS) of 46.48. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does TTK Healthcare pay a dividend?
TTK Healthcare offers a trailing dividend yield of about 1.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is TTK Healthcare financially healthy?
TTK Healthcare carries a debt-to-equity ratio of 0.02x and a current ratio of 5.91x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is TTK Healthcare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TTK Healthcare (TTKHLTCARE) the key facts are: market cap ₹1,422 Crore, P/E 21.6x, revenue ₹857 Crore, 52-week range 735-1359.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track TTK Healthcare's full fundamentals live
Get TTK Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.